Craft
  • Home
  •  / ADC Therapeutics
ADC Therapeutics

ADC Therapeutics

Preclinical Phase Products (Solid Tumor)

2

Sep, 2019

Revenue

$33.9 M

FY, 2021

Market Capitalization

$420.4 M

2022-09-19

ADC Therapeutics Summary

Company summary

Overview
ADC Therapeutics is a biotechnology company that focuses on the development of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and haematological cancers. The company employs monoclonal antibodies specific to particular tumour antigens conjugated to a novel class of highly potent pyrrolobenzodiazepine-based warheads to selectively kill cancer cells.
Type
Public
Founded
2010
HQ
Epalinges, CH | view all locations
Website
http://adctherapeutics.com/
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Ron Squarer
  • Stephen Evans-Freke

    Stephen Evans-Freke, Non-Executive Director

    • Peter B. Corr

      Peter B. Corr, Non-Executive Director

      • Joseph Camardo

        Joseph Camardo, Senior Vice President and Chief Medical Officer

      Operating MetricsView all

      Preclinical Phase Products (Solid Tumor)

      2

      Sep, 2019

      Clinical Phase Products (Solid Tumor)

      2

      Sep, 2019

      Clinical Phase Products (Hematology)

      3

      Sep, 2019

      LocationsView all

      4 locations detected

      • Epalinges, Vaud HQ

        Switzerland

        3B Route de la Corniche

      • New Providence, NJ

        United States

        430 Mountain Ave

      • San Mateo, CA

        United States

        1510 Fashion Island Blvd #205

      • Greater London, England

        United Kingdom

        Queen Mary Innovation Centre 42 New Rd

      ADC Therapeutics Financials

      Summary financials

      Revenue (FY, 2021)
      $33.9M
      Gross profit (FY, 2021)
      $32.6M
      Net income (FY, 2021)
      ($230.0M)
      Cash (FY, 2021)
      $466.5M
      EBIT (FY, 2021)
      ($268.0M)
      Enterprise value
      $55.6M

      Footer menu